+ Follow INTERFERON Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 275092
[Title] => Treatment of chronic hepatitis B: Who to treat, what to use, and for how long?
[Summary] => Chronic hepatitis B infection continues to be a major public health concern worldwide. The natural history of the disease can be divided into 4 different phases: immune tolerance, immune clearance, inactive carrier, and reactivation. The goals of treatment are sustained viral suppression, normalization of ALT, and improvement in liver histology. Antiviral agents in current use include standard interferon, lamivudine, and adefovir.
[DatePublished] => 2005-04-24 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 267041
[Title] => Current status of HCV therapy
[Summary] => Major advances have been made in the treatment of chronic hepatitis C during the last 10 years, but major challenges remain, since treatment with pegylated interferons and ribavirin is effective in only around 55 percent of patients. Newer therapies are needed for the increasing numbers of patients who do not respond to relapse after current treatments with pegylated in interferons and ribavirin.
[DatePublished] => 2004-12-05 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
INTERFERON
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 275092
[Title] => Treatment of chronic hepatitis B: Who to treat, what to use, and for how long?
[Summary] => Chronic hepatitis B infection continues to be a major public health concern worldwide. The natural history of the disease can be divided into 4 different phases: immune tolerance, immune clearance, inactive carrier, and reactivation. The goals of treatment are sustained viral suppression, normalization of ALT, and improvement in liver histology. Antiviral agents in current use include standard interferon, lamivudine, and adefovir.
[DatePublished] => 2005-04-24 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 267041
[Title] => Current status of HCV therapy
[Summary] => Major advances have been made in the treatment of chronic hepatitis C during the last 10 years, but major challenges remain, since treatment with pegylated interferons and ribavirin is effective in only around 55 percent of patients. Newer therapies are needed for the increasing numbers of patients who do not respond to relapse after current treatments with pegylated in interferons and ribavirin.
[DatePublished] => 2004-12-05 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
abtest
